HER2 status predicts for upfront AI benefit: A TRANS-AIOG meta-analysis of 12,129 patients from ATAC, BIG 1-98 and TEAM with centrally determined HER2

JMS Bartlett; I Ahmed; MM Regan; I Sestak; EA Mallon; P Dell'Orto; B Thurlimann; Caroline Seynaeve; H Putter; CJH van de Velde; CL Brookes; JF Forbes; G Viale; J Cuzick; M Dowsett; DW Rea

doi:10.1016/j.ejca.2017.03.033

HER2 status predicts for upfront AI benefit: A TRANS-AIOG meta-analysis of 12,129 patients from ATAC, BIG 1-98 and TEAM with centrally determined HER2

JMS Bartlett
, I Ahmed
, MM Regan
, I Sestak
, EA Mallon
, P Dell'Orto
, B Thurlimann
, Caroline Seynaeve
, H Putter
, CJH van de Velde
, CL Brookes
, JF Forbes
, G Viale
, J Cuzick
, M Dowsett
, DW Rea

Medical Oncology

Research output: Contribution to journal › Article › Academic › peer-review

20 Citations (Scopus)

Original language	Undefined/Unknown
Pages (from-to)	129-138
Number of pages	10
Journal	European Journal of Cancer
Volume	79
DOIs	https://doi.org/10.1016/j.ejca.2017.03.033
Publication status	Published - 2017

Research programs

EMC MM-03-86-01

Access to Document

10.1016/j.ejca.2017.03.033

http://hdl.handle.net/1765/99538

Cite this

Bartlett, JMS., Ahmed, I., Regan, MM., Sestak, I., Mallon, EA., Dell'Orto, P., Thurlimann, B., Seynaeve, C., Putter, H., van de Velde, CJH., Brookes, CL., Forbes, JF., Viale, G., Cuzick, J., Dowsett, M., & Rea, DW. (2017). HER2 status predicts for upfront AI benefit: A TRANS-AIOG meta-analysis of 12,129 patients from ATAC, BIG 1-98 and TEAM with centrally determined HER2. European Journal of Cancer, 79, 129-138. https://doi.org/10.1016/j.ejca.2017.03.033

@article{7f5f8584bbce4a2daf19cf681c34f67f,

title = "HER2 status predicts for upfront AI benefit: A TRANS-AIOG meta-analysis of 12,129 patients from ATAC, BIG 1-98 and TEAM with centrally determined HER2",

author = "JMS Bartlett and I Ahmed and MM Regan and I Sestak and EA Mallon and P Dell'Orto and B Thurlimann and Caroline Seynaeve and H Putter and \{van de Velde\}, CJH and CL Brookes and JF Forbes and G Viale and J Cuzick and M Dowsett and DW Rea",

year = "2017",

doi = "10.1016/j.ejca.2017.03.033",

language = "Undefined/Unknown",

volume = "79",

pages = "129--138",

journal = "European Journal of Cancer",

issn = "0959-8049",

publisher = "Elsevier Ltd.",

}

Bartlett, JMS, Ahmed, I, Regan, MM, Sestak, I, Mallon, EA, Dell'Orto, P, Thurlimann, B, Seynaeve, C, Putter, H, van de Velde, CJH, Brookes, CL, Forbes, JF, Viale, G, Cuzick, J, Dowsett, M & Rea, DW 2017, 'HER2 status predicts for upfront AI benefit: A TRANS-AIOG meta-analysis of 12,129 patients from ATAC, BIG 1-98 and TEAM with centrally determined HER2', European Journal of Cancer, vol. 79, pp. 129-138. https://doi.org/10.1016/j.ejca.2017.03.033

TY - JOUR

T1 - HER2 status predicts for upfront AI benefit: A TRANS-AIOG meta-analysis of 12,129 patients from ATAC, BIG 1-98 and TEAM with centrally determined HER2

AU - Bartlett, JMS

AU - Ahmed, I

AU - Regan, MM

AU - Sestak, I

AU - Mallon, EA

AU - Dell'Orto, P

AU - Thurlimann, B

AU - Seynaeve, Caroline

AU - Putter, H

AU - van de Velde, CJH

AU - Brookes, CL

AU - Forbes, JF

AU - Viale, G

AU - Cuzick, J

AU - Dowsett, M

AU - Rea, DW

PY - 2017

Y1 - 2017

U2 - 10.1016/j.ejca.2017.03.033

DO - 10.1016/j.ejca.2017.03.033

M3 - Article

C2 - 28494403

SN - 0959-8049

VL - 79

SP - 129

EP - 138

JO - European Journal of Cancer

JF - European Journal of Cancer

ER -